



Antiretroviral Prices in 2023

This publication is a compilation of the prices (in US\$ per person per year) of antiretroviral (ARV) drugs in low- and middle-income countries (LMICs) in 2023, as quoted by the corporations that produce them. The price in brackets corresponds to the price of one unit (tablet, capsule, mL, etc). Products included in the World Health Organization (WHO) list of prequalified medicines or approved by the US Food and Drug Administration (as of November 2023) are in bold. Each originator corporation applies its own eligibility criteria for discounting ARVs. Countries that are eligible for a discount from one corporation may not be eligible for discounts from others. Usually, corporations create two to three groups of discount-eligible countries, often called ‘Category 1’ (countries that are eligible for the highest discounts) and ‘Category 2/3’ (countries that are offered a lower discount).

Paediatric formulations are highlighted in pink. Prices for paediatric products are estimated, based on WHO-recommended dosing, for the 10 kg weight band. When it was not possible to calculate dosing for the 10 kg weight band, the unit price was used.

The prices paid by the Global Fund to Fight AIDS, Tuberculosis and HIV (Global Fund) have been added as a comparison and additional reference. The prices indicated are the lowest reported for each item in the April 2024 update of Global Fund’s Pooled Procurement Mechanism (PPM) prices, which accounts for larger pack sizes and cartonless products where applicable.

The lowest price for WHO’s first-line HIV treatment for adults (TDF/3TC/DTG) is US\$37 per person per year. For WHO’s first-line treatment for children, it is \$30 for the new paediatric fixed-dose combination (FDC) of ABC/3TC/DTG (based on 10kg).

Generic corporations producing dolutegravir (DTG) or DTG-based FDCs provided price ranges, reflecting the royalties imposed for certain countries as per the voluntary license for DTG between pharmaceutical corporation ViiV and the Medicines Patent Pool, and the lowest prices are provided here. Royalties paid by generic manufacturers to ViiV vary by country: 5% in India, Vietnam, Philippines and Moldova; 7.5% in Indonesia, Egypt, Morocco, Armenia and Ukraine; 10% in Turkmenistan.¹

Note that where multiple pack sizes are available (i.e., 30, 90, 180 tabs), with or without cartons, the lowest price is included in the table.

¹ <https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg>

ARVs	Daily Dose	Originator Corporation		Global Fund PPM Prices									
atazanavir (ATV)		BMS			Emcure								
		Cat 1	Cat 2										
300mg capsule	1	\$1606 (\$4.40)	\$803 (\$2.20)		\$243 (\$0.667)								
atazanavir/ritonavir (ATV/r)		No Originator		Global Fund	Emcure	Lupin	Mylan						
300/100mg tablet	1	N/A		\$128 (\$0.35)	\$133 (\$0.365)	\$135 (\$0.370)	\$164 (\$0.450)						
darunavir (DRV)		Janssen		Global Fund	Cipla	Hetero	Mylan						
		Cat 1	Cat 2										
75mg tablet	2	\$82 (\$0.113)	N/A	\$99 (\$0.135)									
150mg tablet	6	\$493 (\$0.225)		N/A									
400mg tablet	2	\$438 (\$0.600)		\$487 (\$0.667)									
600mg tablet	2	\$657 (\$0.900)		\$511 (\$0.700)	\$572 (\$0.783)	\$548 (\$0.750)	\$511 (\$0.700)						
dolutegravir (DTG)		ViiV		Global Fund	Aurobindo	Cipla	Emcure	Hetero	Macleods	Micro	Mylan	Sun	Strides
10mg dispersible tablet	2	N/A		\$33 (\$0.044)					\$37 (\$0.050)		\$37 (\$0.050)		
50mg tablet	1	POA		\$15 (\$0.040)	\$22	\$28	\$22 (\$0.061)	\$21	\$77 (\$0.053)	\$23	\$18 (\$0.049)	\$24 (\$0.065)	\$43 (\$0.117)

					(\$0.06 0)	(\$0.0 77)		(\$0.0 58)		(\$0.06 3)		
efavirenz (EFV)		Merck		Global Fund	Sun Pharm a							
		Cat 1	Cat 2									
200mg tablet (single scored)	3	\$394 (\$0.360)	N/A									
600mg tablet	1	\$237 (\$0.650)	N/A		\$32 (\$0.08 8)							
etravirine (ETV)		Janssen		Global Fund								
		Cat 1	Cat 2									
100mg tablet	4	\$438 (\$0.300)	N/A	\$438 (\$0.30)								
lamivudine (3TC)		ViiV		Global Fund	Hetero	Macl eods						
10mg/ml oral suspension	10 mL	POA		\$34 (\$0.009)	\$35 (\$0.01 0)	\$46 (\$0.0 13)						
lopinavir/riton avir (LPV/r)		AbbVie		Global Fund	Aurobi ndo	Cipla	Hetero	Myla n				
		Cat 1	Cat 2									
40mg/10mg granules	4	N/A		\$206 (\$0.141)				\$220 (\$0.1 51)				
40mg/10mg pellets	4	N/A		\$210 (\$0.144)		\$219 (\$0.1 50)						
100/25mg tablet	3	\$119 (\$0.108)	\$278 (\$0.2 54)	\$100 (\$0.092)	\$128 (\$0.11 7)		\$146 (\$0.133)	\$128 (\$0.1 17)				
200/50mg tablet	4	\$243 (\$0.167)	\$740 (\$0.5 07)	\$218 (\$0.150)	\$231		\$304 (\$0.208)	\$227 (\$0.1 55)				

					(\$0.158)					
nevirapine (NVP)		Boehringer Ingelheim		Global Fund	Aurobindo	Cipla				
10mg/ml suspension	20mL	N/A		\$128 (\$0.018)	\$128 (\$0.018)	\$116 (\$0.016)				
50mg tablet for oral suspension	4	N/A				\$48 (\$0.033)				
raltegravir (RAL)		Merck		Global Fund						
		Cat 1	Cat 2							
100mg powder/sachet	2	\$694 (\$0.95)	N/A	N/A						
25mg tablet	XX	(\$0.300)	Case-by-case							
100mg tablet	XX	(\$0.600)								
400mg tablet	2	\$675 (\$0.925)								
ritonavir (RTV)		Abbvie		Global Fund	Cipla	Hetero	Mylan			
		Cat 1	Cat 2							
25mg tablet		NA		(\$0.10)			(\$0.10)			
100mg tablet	1	\$91 (\$0.125)	\$624 (\$0.855)	\$170 (\$0.233)	\$155 (\$0.213)	\$170 (\$0.233)	\$170 (\$0.233)			
tenofovir (TDF)		Gilead		Global Fund	Aurobindo	Hetero	Macleods	Mylan	Strides	
300mg tablet	1	No response at time of publication		\$29 (\$0.080)	\$49 (\$0.133)	\$30 (\$0.083)	\$37 (\$0.100)	\$23 (\$0.062)	\$37 (\$0.100)	

zidovudine (AZT)		ViiV	Global Fund	Aurobindo	Cipla	Hetero						
10mg/ml oral solution	24mL	POA	\$91 (\$0.010)	\$73 (\$0.008)	\$171 (\$0.020)	\$84 (\$0.010)						
ABC/3TC		ViiV	Global Fund	Aurobindo	Cipla	Hetero	Macleods	Mylan	Sun			
120/60mg dispersible tablet	2	N/A	\$65 (\$0.089)		\$74 (\$0.101)			\$79 (\$0.108)				
600/300mg tablet	1	POA	\$96 (\$0.262)	\$110 (\$0.300)		\$97 (\$0.267)	\$111 (\$0.303)	\$116 (\$0.317)	\$108 (\$0.297)			
ABC/3TC/DTG		ViiV	Global Fund	Aurobindo								
60mg/30mg/5mg dispersible tablet	1	N/A	\$120 (\$0.083)									
600mg/300mg/50mg tablet	1	POA	\$243 (\$0.667)	\$243 (\$0.667)								
TDF/FTC		Gilead	Global Fund	Cipla	Emcure	Hetero	Lupin	Macleods	Micro	Mylan	Strides	Sun
300/200mg tablet	1	No response at time of publication	\$40 (\$0.111)	\$58 (\$0.158)	\$46 (\$0.127)	\$49 (\$0.133)	\$47 (\$0.128)	\$61 (\$0.167)	\$58 (\$0.158)	\$47 (\$0.128)	\$49 (\$0.133)	\$44 (\$0.120)
TDF/3TC		No originator	Global Fund	Cipla	Hetero	Lupin	Micro	Mylan	Sun	Macleods		
300/300mg tablet	1		\$38 (\$0.104)	\$54 (\$0.147)	\$43 (\$0.117)	\$50 (\$0.138)	\$43	\$40 (\$0.108)	\$40 (\$0.110)	\$49 (\$0.133)		

								(\$0.118)				
TDF/3TC/EFV		No originator	Global Fund	Hetero	Macleods	Mylan						
300/300/400mg tablet	1		\$52 (\$0.142)	\$61 (\$0.167)	\$72 (\$0.197)	\$52 (\$0.142)						
TDF/3TC/DTG		No Originator	Global Fund	Aurobindo	Cipla	Emcur	Hetero	Lupin	Macleods	Mylan	Strides	Sun
300mg/300mg/50mg	1	N/A	\$38 (\$0.103)	\$40 (\$0.108)	\$37 (\$0.101)	\$41 (\$0.113)	\$46 (\$0.125)	\$43 (\$0.117)	\$43 (\$0.119)	\$44 (\$0.119)	39 (0.106)	46 (0.127)
AZT/3TC		ViiV	Global Fund	Cipla	Hetero	Macleods	Micro	Mylan	Sun			
60/30mg tablet	4		\$46 (\$0.032)	\$51 (\$0.035)				\$97 (\$0.067)				
300/150mg tablet	2	POA	\$65 (\$0.089)	\$79 (\$0.108)	\$79 (\$0.108)	\$91 (\$0.125)	\$69 (\$0.095)	\$67 (0.092)	\$66 (\$0.090)			
cabotegravir (CAB)		ViiV										
		Cat 1	Cat 2									
30mg tablet (Price in GBP)	1	£490 (£1.34)	POA									
CAB-LA		ViiV										
		Cat 1	Cat 2									
600mg/3ml vial (Price in GBP)	2023	£148 (£24.72)	POA									
	2024	£141 (£23.50)	POA									